Structured evidence table for Cacao Flavanol Anxiety Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Cacao Flavanol Anxiety Randomized Trial | It includes increased interferons, tumor necrosis factor, bradykinin, serine proteases, and soluble thrombomodulin, and altered clot lysis times [,,,,], all of which contribute to microvascular and thrombotic disease [,]. | 2 | Munguía Levy (2026) | Effects of Cacao Flavonoids in Long COVID-19 Patients with Chronic Fatigue: FLALOC, a Placebo-Controlled Randomized Clinical Trial |
| Cacao Flavanol Anxiety Randomized Trial | A myriad of causes can trigger fatigue, but its development has been strongly associated with post-viral phases of infection. | 2 | Munguía Levy (2026) | Effects of Cacao Flavonoids in Long COVID-19 Patients with Chronic Fatigue: FLALOC, a Placebo-Controlled Randomized Clinical Trial |
| Cacao Flavanol Anxiety Randomized Trial | Long COVID-associated fatigue has been causally linked to sustained inflammation and to endothelial and mitochondrial dysfunction. | 2 | Munguía Levy (2026) | Effects of Cacao Flavonoids in Long COVID-19 Patients with Chronic Fatigue: FLALOC, a Placebo-Controlled Randomized Clinical Trial |
| Cacao Flavanol Anxiety Randomized Trial | 1 2 3 4 5 6 7 8 Coronavirus disease 2019 (COVID-19) is caused by the acute respiratory syndrome coronavirus 2 (SARS-CoV-2). | 2 | Munguía Levy (2026) | Effects of Cacao Flavonoids in Long COVID-19 Patients with Chronic Fatigue: FLALOC, a Placebo-Controlled Randomized Clinical Trial |
| Cacao Flavanol Anxiety Randomized Trial | 9 12 Some factors that increase the possibility of developing DN are the duration of diabetes, high glycated hemoglobin (HbA1c) values, smoking, obesity, high blood pressure, and dyslipidemia, all of which are metabolic risk factors and are associated with persistent inflammation and oxidative stress [,]. | 2 | Kababie-Ameo Rebeca (2025) | Effect of Cocoa Supplementation on the Biochemical and Clinical Profile and the Somatosensory Processing of Diabetic Peripheral and Autonomic Neuropathy: A Randomized Clinical Trial |
| Cacao Flavanol Anxiety Randomized Trial | 13 14 15 16 The Hoffman reflex (hereafter referred to as the H-reflex) is produced by an electrical pulse applied to a peripheral nerve and is recorded in a specific muscle, allowing for an evaluation of the nerve fibers and associated neural circuits under both normal and pathological conditions []. | 2 | Kababie-Ameo Rebeca (2025) | Effect of Cocoa Supplementation on the Biochemical and Clinical Profile and the Somatosensory Processing of Diabetic Peripheral and Autonomic Neuropathy: A Randomized Clinical Trial |
| Cacao Flavanol Anxiety Randomized Trial | 12 17 18 Currently, the management of DN involves lifestyle changes to control glycemia and associated risk factors, along with pharmacological treatment for pain relief, such as Pregabalin, Duloxetine, Gabapentin, and Amitriptyline. | 2 | Kababie-Ameo Rebeca (2025) | Effect of Cocoa Supplementation on the Biochemical and Clinical Profile and the Somatosensory Processing of Diabetic Peripheral and Autonomic Neuropathy: A Randomized Clinical Trial |
| Cacao Flavanol Anxiety Randomized Trial | 1 Type 2 diabetes (T2D) is a metabolic disease characterized by the progressive loss of insulin secretion with different grades of insulin resistance and is considered the most common type of diabetes, representing more than 90% of all cases []. | 2 | Kababie-Ameo Rebeca (2025) | Effect of Cocoa Supplementation on the Biochemical and Clinical Profile and the Somatosensory Processing of Diabetic Peripheral and Autonomic Neuropathy: A Randomized Clinical Trial |
Source documents